Abstract
A risk for genital malformations is expected after the use of drugs with androgenic or anti-androgenic properties because the normal male genital development is driven by androgens. In the present material, only very few exposures were found for these drug categories. Use of prolactin inhibitors or sex hormones is strongly linked to subfertility in the woman, and an increased malformation risk may be explained by a direct effect of subfertility, but it is difficult to separate the effect of drugs from that of underlying condition. There are signs that estrogens (or estrogens combined with gestagens) carry a higher risk than only gestagens. Such a difference like the difference between gonadotropins and clomiphene may be explained by differences in the nature and degree of underlying subfertility. The most remarkable finding is the high risk of a neural tube defect after maternal use of gonadotropins or clomiphene—this phenomenon is also seen after in vitro fertilization, usually performed after gonadotropin treatment. The absolute risk is, however, low.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aarskog D. Clinical and cytogenetic studies in hypospadias. Acta Paediatr Scand. 1970;203(Suppl. 203):1–62. J Obstet Gynaecol. 1989;29:176–179.
Al-Suleiman SA, Najashi S, Rahman J, Rahman MS. Outcome of treatment with bromocriptine in patients with hyperprolactinemia. Aust N Z J Obstet Gynecol. 1989;29:176–9.
Asch RH, Greenblatt RB. Update on the safety and efficiency of clomiphene citrate as a therapeutic agent. J Reprod Med. 1976;17:175–80.
Benedum CN, Yazdy MM, Parker RE, Mitchell AA, Werler MM. Associations of clomiphene and assisted technologies with the risk of neural tube defects. Am J Epidemiol. 2016;183:977–87.
Bernard N, Elefant E, Carlier P, Tebacher M, Barjhoux CE, Bos-Thompson MA, Amar E, Descotes J, Vial T. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. BJOG. 2013;120:568–75.
Bracken MB. Oral contraception and congenital malformations in offspring: a review and meta-analysis of the prospective studies. Obstet Gynecol. 1990;76:552–7.
Brouwers MM, Feitz WFJ, Roelofs LAJ, Kiemeney LALM, de Gier RPE, Roeleveld N. Hypospadias: a transgenerational effect of diethylstilbestrol. Hum Reprod. 2006;21:666–9.
Dudás I, Gidai J, Czeizel AE. Population-based case-control teratogenic study of hydroxyprogesterone treatment during pregnancy. Congenit Anom (Kyoto). 2006;46:194–8.
Ericson A, Källén B, Lindsten J. Lack of correlation between contraceptive pills and Down’s syndrome. Acta Obstet Gynecol Scand. 1983;62:511–4.
Harris EL. Genetic epidemiology of hypospadias. Epidemiol Rev. 1990;12:19–40.
Heinonen OP, Sloane D, Monson RR, Hook EB, Shapiro S. Cardiovascular birth defects and antenatal exposure to sex hormones. N Engl J Med. 1977;296:67–70.
Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence. A report of seven cases including six clear cell carcinomas (so-called meso-nephromas). Cancer. 1970;25:745–57.
Hook EB. Cardiovacular birth defects and prenatal exposure to female sex hormones: a reevaluation of data reanalysis from a large prospective analysis. Teratology. 1994;49:162–6.
Janerich DT, Flink EM, Keogh MD. Down’s syndrome and oral contraceptive usage. Br J Obstet Gynecol. 1976;83:617–20.
Källén B. Maternal use of oral contraceptives and Down syndrome. Contraception. 1989;39:503–6.
Källén BAJ, Martinez-Frías ML, Castilla EE, Robert E, Lancaster PAL, Kringelbach M, Mutchinik OM, Mastroiacovo P. Hormone therapy during pregnancy and isolated hypospadias: an international case-control study. Int J Risk Saf Med. 1992;3:183–98.
Källén B, Finnström O, Lindam A, Nilsson E, Nygren K-G, Otterblad Olausson P. Congenital malformations in infants born after in vitro fertilization in Sweden. Birth Defects Res A Clin Mol Teratol. 2010;88:137–43.
Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr. 1987;65:823–7.
Lejeune J, Prieur M. Contraceptives oraux et trisomy 21. Ann Génet. 1979;22:61–6.
Martinez-Frías ML, Bermejo E, Rodriguez-Pinilla E, Prieto L. Periconceptional exposure to contraceptive pills and risk for Down syndrome. J Perinatol. 2001;21:288–92.
Molitch ME. Management of the pregnant patient with a prolactinoma. Eur J Endocrinol. 2015;172:R205–13.
Rastogi A, Bhadada SK, Bhansali A. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecol Endocrinol. 2017;33:270–3.
Reefhuis J, Honein MA, Schieve LA, Rasmussen SA, the National Birth Defects Prevention Study. Use of clomiphene citrate and birth defects, National Birth Defects Prevention Study, 1997–2005. Hum Reprod. 2011;26:451–7.
Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A, Rocchi F, Gangi E, Paracchi S, Gasperi M, Lavezzari M, Nicolosi AE, Ferrero S, Landi ML, Beck-Peccoz P, Bonati M. Pregnancy outcome after cabergoline treatment in early weeks of gestation. Reprod Toxicol. 2002;16:791–3.
Robert E, Musatti L, Piscitelli G, Ferrari CI. Pregnancy outcome after treatment with the ergot derivative, cabergoline. Reprod Toxicol. 1996;10:333–7.
Schardein JL. Congenital abnormalities and hormones during pregnancy. A clinical review. Teratology. 1980;22:251–70.
Sharma S, Ghosh S, Singh S, Chakravarty A, Ganesh A, Rajani S, Chakravarty BN. Congenital malformations among babies born following letrozole of clomiphene for infertility treatment. PLoS One. 2014;9:e108219. https://doi.org/10.1371/journal.pone.0108219.
Tulandi T, Martin J, Al-Fadhli R, Kabli N, Forman R, Hitkari J, Librach C, Greenblatt E, Casper RF. Congenital malformations among 911 newborns conceived after infertility treatment with letrozole or clomiphene citrate. Fertil Steril. 2006;85:1761–5.
Waller DK, Gallaway MS, Taylor LG, Ramadhani TA, Canfield MA, Scheuerle A, Hernandez-Diaz S, Louik C, Correa A. Use of oral contraceptives in pregnancy and major structural defects in offspring. Epidemiology. 2010;21:232–9.
Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug Saf. 1996;14:228–38.
Weller A, Daniel S, Koren G, Lunenfeld E, Levy A. The fetal safety of clomiphene citrate: a population-based retrospective cohort study. BJOG. 2017;124:1664–70. https://doi.org/10.1111/1471-0528.14651.
Wiseman RA, Dodds-Smith IC. Cardiovascular birth defects and antenatal exposure to female sex hormones: a reevaluation of some base data. Teratology. 1984;30:359–70.
Zander J, Muller HA. Ũber die Methylandrostendiol-Behandlung während einer Schwangerschaft. Geburthilfe Frauenheilk. 1953;13:216–22.
Zhang L, Chen J, Wang Y, Ren F, Yu W, Cheng L. Pregnancy outcome after levonorgestrel-only emergency contraception failure: a prospective cohort study. Hum Reprod. 2009;34:1605–11.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Källén, B. (2019). Maternal Use of Prolactin Inhibitors or Sex Hormones and Infant Congenital Malformations. In: Maternal Drug Use and Infant Congenital Malformations. Springer, Cham. https://doi.org/10.1007/978-3-030-17898-7_11
Download citation
DOI: https://doi.org/10.1007/978-3-030-17898-7_11
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-17897-0
Online ISBN: 978-3-030-17898-7
eBook Packages: MedicineMedicine (R0)